Oncology
Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
July 10, 2023Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …
FDA grants Priority Review for Astellas Pharma’s BLA for cancer drug
July 6, 2023Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology
Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …
Jacobio Pharma receives CDE approval for pancreatic cancer study in China
July 5, 2023Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial
Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …
Cytovation appoints Olav Hellebø to board of directors
July 5, 2023Business Services Cytovation, Olav Hellebø, Oncology, appointment, board of directors
Cytovation ASA, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has …
AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …
Astellas establishes open innovation hub for tumour microenvironment research
June 29, 2023Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment
Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …
UK nonprofit National Cancer Research Institute to close
June 27, 2023Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology
The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
June 23, 2023Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology
US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …
Zymeworks to open new EU HQ in Dublin, Ireland
June 22, 2023Business Services Dublin, Oncology, Zymeworks, headquarters, regulatory affiars
Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland. Zymework …
FDA approves Pfizer’s HRR mCRPC drug
June 21, 2023Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer
US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
Sirnaomics advances isSCC candidate into late-stage clinical development
June 20, 2023Research and Development FDA, Oncology, Sirnaomics, clinical trial, isSCC
Global RNA therapeutics biopharmaceutical company Sirnaomics has announced that it has advanced its Squamous Cell Carcinoma in situ (isSCC) candidate …
Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership
June 20, 2023Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership
Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …
GSK announces extension of FDA’s review for momelotinib
June 20, 2023Medical Communications FDA, GSK, Oncology, momelotinib, new drug application
GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …
Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis
June 16, 2023Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis
Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …
Takeda and HUTCHMED’s cancer drug shown to prolong overall survival
June 16, 2023Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …
Latest content
FibroFind appoints Lee Borthwick as CEO
